La Jolla Pharmaceutical Shares Rise

La Jolla Pharmaceutical shares were higher 3% in early trade Monday after the company said the U.S. Food and Drug Administration has accepted for review the new drug application for LJPC-501for the treatment of hypotension in adults with distributive or vasodilatory shock who remain hypotensive despite fluid and vasopressor therapy.

The review classification for the application is priority, and the prescription drug user fee act date is Feb. 28. In its letter to the company, the FDA said it does not currently plan to hold an advisory committee meeting to discuss this application.

Leave a Comment